Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
VEGFR2/KDR/Flk-1 Antibody (1B6) - BSA Free, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP236428
Description
VEGFR2/KDR/Flk-1 Monoclonal specifically detects VEGFR2/KDR/Flk-1 in Human samples. It is validated for Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Flow (Cell Surface).Specifications
VEGFR2/KDR/Flk-1 | |
Monoclonal | |
1.0 mg/mL | |
Western Blot 1 ug/ml, Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence 1:50 - 1:100, Immunohistochemistry-Paraffin 5 ug/ml, Flow (Cell Surface) | |
CD309, CD309 antigen, EC 2.7.10, EC 2.7.10.1, Fetal liver kinase 1, fetal liver kinase-1, FLK-1, FLK1tyrosine kinase growth factor receptor, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, vascular endothelial growth factor receptor 2, VEGFR, VEGFR2, VEGFR-2 | |
Mouse | |
Protein G purified | |
RUO | |
Primary | |
Human | |
Purified |
Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin) | |
1B6 | |
Unconjugated | |
P35968 | |
KDR | |
Partial recombinant human VEGFR2 protein (between amino acids 300-600) [Uniprot: P35968] | |
0.1 mg | |
Angiogenesis, Cancer, Cellular Markers, Endothelial Cell Markers, Hematopoietic Stem Cell Markers, HIF Target Genes, Hypoxia, Phospho Specific, Signal Transduction, Stem Cell Markers, Tumor Suppressors, Tyrosine Kinases | |
3791 | |
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. | |
IgG1 κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction